Immatics takes up the Spac baton
First signals of efficacy, at doses thought to have been sub-therapeutic, send the Spac-listed group up 30%.
No knockout blow from Rubius
Rubius shows the first hints of clinical anticancer activity, and is suddenly worth $2.4bn.
Can we freeze them? Yes we can, says Nkarta
The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.
Bayer’s gene therapy juggling act
Two arm’s-length acquisitions and two licensing deals have given Bayer a cell and gene therapy unit; now to bring it all together.
Nantkwest tries to catch the NK cell wave
Nantkwest claims efficacy with its most advanced NK cell therapy but, as ever with Patrick Soon-Shiong companies, it’s complicated.
